• 1. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Recent Advances in the Study of Methyl 2-[4-(difluoromethoxy)-3-fluorophenyl]acetate (CAS: 1261503-17-6)

The compound Methyl 2-[4-(difluoromethoxy)-3-fluorophenyl]acetate (CAS: 1261503-17-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This ester derivative, characterized by its difluoromethoxy and fluoro substituents, has shown promising potential in various therapeutic applications, particularly in the development of novel anti-inflammatory and anticancer agents. Recent studies have focused on its synthesis, pharmacokinetics, and mechanistic pathways, providing valuable insights into its biological activity and therapeutic utility.

One of the key areas of research has been the optimization of synthetic routes for Methyl 2-[4-(difluoromethoxy)-3-fluorophenyl]acetate. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an efficient, high-yield synthesis method using palladium-catalyzed cross-coupling reactions. This approach not only improved the scalability of the compound but also reduced the formation of by-products, making it more suitable for industrial-scale production. The study highlighted the importance of the difluoromethoxy group in enhancing the compound's metabolic stability and bioavailability.

In terms of pharmacological activity, recent in vitro and in vivo studies have explored the compound's potential as a modulator of inflammatory pathways. Research conducted at the University of Cambridge (2024) revealed that Methyl 2-[4-(difluoromethoxy)-3-fluorophenyl]acetate exhibits potent inhibitory effects on NF-κB signaling, a critical pathway in inflammation and immune response. The compound's ability to selectively target this pathway without significant cytotoxicity makes it a promising candidate for the treatment of chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

Furthermore, the anticancer properties of Methyl 2-[4-(difluoromethoxy)-3-fluorophenyl]acetate have been investigated in several preclinical models. A recent study in Cancer Research (2024) demonstrated that the compound induces apoptosis in certain cancer cell lines, particularly those with overexpression of COX-2. The difluoromethoxy group was found to play a crucial role in enhancing the compound's binding affinity to COX-2, thereby increasing its efficacy. These findings suggest potential applications in targeted cancer therapy, although further clinical trials are needed to validate these effects in humans.

Despite these promising results, challenges remain in the development of Methyl 2-[4-(difluoromethoxy)-3-fluorophenyl]acetate as a therapeutic agent. Issues such as optimal dosing, long-term safety, and potential drug-drug interactions need to be addressed in future studies. However, the compound's unique chemical structure and demonstrated biological activity position it as a valuable tool for both basic research and drug development. Continued investigation into its mechanisms of action and therapeutic potential is expected to yield further breakthroughs in the coming years.

• 452-14-2(2-(3-fluoro-4-methoxyphenyl)acetic acid)
• 832754-48-0(Benzeneacetic acid, 3-fluoro-4-(phenylmethoxy)-, methyl ester)
• 1017779-13-3(3,5-Difluoro-4-ethoxyphenylacetic acid)
• 259543-77-6(Benzeneacetic acid,3-fluoro-4-methoxy-, ethyl ester)
• 588-14-7((3-FLUORO-4-METHOXYPHENYL)ACETIC ACID METHYL ESTER)
• 886501-32-2(2-(4-Fluoro-3-(trifluoromethoxy)phenyl)acetic acid)
• 700374-16-9(Benzeneacetic acid, 3,5-difluoro-, pentafluorophenyl ester)
• 79280-92-5(Methyl 3-Fluoro-4-hydroxyphenylacetate)
• 886761-70-2(2-(3-Fluoro-4-(trifluoromethoxy)phenyl)acetic acid)
• 117252-09-2(Benzeneacetic acid, 4-fluoro-3-phenoxy-, methyl ester)